In today’s oncology landscape, a critical problem persists: approximately 75% of cancer drugs fail to deliver benefits due to genetic mismatches. Despite medical advancements, many treatments are prescribed without considering a patient’s unique genetic profile. Patients endure harsh side effects with little therapeutic gain.
Traditional medicine has a flaw — it treats diseases based on broad population data. Yet, each patient’s genetics can determine whether a drug will be effective, especially in cases like HER2+ breast cancer.
At EthicaMeds, we are transforming cancer treatment through personalized medicine. Our proprietary GigaAssay™ technology tests the functional impact of millions of genetic variants, including the full spectrum of 5,886 HER2+ mutations. Unlike conventional tests, we assess how a patient’s unique genetic profile responds in real-world environments.
This precision approach means we can predict with near 100% accuracy which cancer drugs won’t work, saving time, reducing suffering, and increasing survival odds. With over 112 newly identified breast cancer-associated mutations, EthicaMeds ensures no genetic detail is overlooked.
Personalized medicine isn’t just a trend — it’s the ethical, effective future of healthcare. EthicaMeds is proud to lead the charge, ensuring every breast cancer patient receives the right treatment based on their individual genetics.
